Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Department of Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cell Death Dis. 2018 Feb 15;9(3):263. doi: 10.1038/s41419-018-0333-3.
NIT1 protein has been reported to be a potential tumour suppressor in tumour progression. However, little is known about the specific role of NIT1 in tumour development and progression. In this study, we confirmed the specific effects of NIT1 in the regulation of colorectal carcinoma cell proliferation. Here, we showed that NIT1 was significantly downregulated in colorectal cancer tissues compared with that in adjacent normal tissues. The decreased expression of NIT1 was significantly correlated with poor differentiation and more serosal invasion. Functional experiments showed that NIT1 inhibited CRC cell growth both in vitro and in vivo. NIT1 induced cell cycle arrest and apoptosis. Furthermore, NIT1 recruited Smad2/3 to the TGFβ receptor and activated the TGFβ-Smad2/3 pathway by interacting with SARA and SMAD2/3 in CRC. Further study has shown that SMAD3 directly binds to the promoter regions of NIT1 and enhances the transcription of NIT1. Together, our findings indicate that NIT1 suppresses CRC proliferation through a positive feedback loop between NIT1 and activation of the TGFβ-Smad signalling pathway. This study might provide a new promising strategy for CRC.
NIT1 蛋白已被报道在肿瘤进展中是一种潜在的肿瘤抑制因子。然而,关于 NIT1 在肿瘤发生和发展中的具体作用知之甚少。在这项研究中,我们证实了 NIT1 在调节结直肠癌细胞增殖中的特定作用。结果显示,与邻近正常组织相比,NIT1 在结直肠癌组织中明显下调。NIT1 的表达降低与分化不良和浆膜侵犯程度增加显著相关。功能实验表明,NIT1 抑制 CRC 细胞的体外和体内生长。NIT1 诱导细胞周期停滞和细胞凋亡。此外,NIT1 通过与 SARA 和 SMAD2/3 相互作用,招募 Smad2/3 到 TGFβ 受体,并激活 TGFβ-Smad2/3 通路。进一步的研究表明,SMAD3 直接结合 NIT1 的启动子区域,并增强 NIT1 的转录。综上所述,我们的研究结果表明,NIT1 通过 NIT1 与 TGFβ-Smad 信号通路的激活之间的正反馈环抑制 CRC 的增殖。这项研究可能为 CRC 提供一种新的有前途的治疗策略。